Literature DB >> 15513897

Potent inhibition of recombinant human cytochrome p-450 1A1 by pentamethoxystilbene.

Sang-Kwang Lee1, Yongmo Kim, Mie Young Kim, Young-Jin Chun, Sanghee Kim.   

Abstract

Previously it was reported that various hydroxystilbene compounds strongly inhibit human cytochrome P-450 1 enzymes and were postulated as candidate chemopreventive agents. In this study, the inhibitory potential of P-450 1 enzyme activities by 3,5,3,4,5-pentamethoxystilbene (PMS), a synthetic stilbene compound, was evaluated with the Escherichia coli (E. coil) membranes of recombinant human cytochrome P-450 1A1, 1A2, or 1B1 coexpressed with human NADPH-P-450 reductase. PMS produced a significant inhibition of ethoxyresorufin O-deethylation (EROD) activities with IC50 values of 0.14, 934, and 3.2 M for 1A1, 1A2, and 1B1, respectively. PMS did not significantly inhibit EROD activities in human liver microsomes. To elucidate the mechanism of inhibition by PMS, kinetic studies were performed. Analysis of the mode of inhibition indicated a mixed-type inhibition of P-450 1A1. The inhibition of P-450 1A1-mediated EROD activity by PMS was not irreversible-mechanism based. The loss of EROD activity of P-450 1A1 with PMS was blocked by trapping agents such as glutathione, N-acetylcysteine, or dithiothreitol. Moreover, PMS significantly suppressed P-450 1A1-mediated EROD activity and P-450 1A1 gene expression in HepG2 cells induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Taken together, the results suggested that PMS is a potent and selective inhibitor of human P-450 1A1 and may be considered for use as a cancer chemopreventive agent in humans.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15513897     DOI: 10.1080/15287390490514642

Source DB:  PubMed          Journal:  J Toxicol Environ Health A        ISSN: 0098-4108


  2 in total

Review 1.  Cytochrome P450 family 1 inhibitors and structure-activity relationships.

Authors:  Jiawang Liu; Jayalakshmi Sridhar; Maryam Foroozesh
Journal:  Molecules       Date:  2013-11-25       Impact factor: 4.411

Review 2.  Therapeutic Versatility of Resveratrol Derivatives.

Authors:  Waqas Nawaz; Zhongqin Zhou; Sa Deng; Xiaodong Ma; Xiaochi Ma; Chuangang Li; Xiaohong Shu
Journal:  Nutrients       Date:  2017-10-29       Impact factor: 5.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.